sign in sign up
<<
Home , Aplindore, Corynanthine, Istradefylline, Nafadotride, Pardoprunox, Piribedil

Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Table S1: pharmacological profile of the assessed in the MPTP-lesioned primate

category references

D-(9)-THC (Felder et al., CB1,2 (dronabinol) agonist 1995)

(-)-3-(3- (Arnt et al.,

hydroxyphenyl)-N-n- D2 agonist, s D2 agonist 1983; Iyengar et

propylpiperone al., 1991)

(+)-4-propyl-9- (Martin et al., hydroxynaphthoxazine D2 agonist, a2 ligand D2 agonist 1985) (PHNO)

(+)-N-n-propyl-3-(3- (Close et al., hydroxyphenyl)- D2 agonist D2 agonist 1990) [(+)-3PPP]

(-)-N-n-propyl-3-(3- (Close et al., hydroxyphenyl)- D2 D2 partial agonist 1990) piperidine (-)-3PPP

(Loschmann et (-)-N-0437 D2-like agonist D2 agonist al., 1989)

(Burstein et al., (-)-OSU-6162 (PNU- D2 partial agonist, 5-HT2A D2 partial agonist 2011; Carlsson 96,391) partial agonist et al., 2011)

2-amino-5,6- (Mulder et al., D2 agonist D2 agonist dihydroxytetralin 1980; Gower

1 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (N,N-dipropyl A-5,6- and Marriott,

DTN) 1982)

(Tricklebank et

5-MDOT (5-MeO- non-selective 5-HT al., 1985; 5-HT agonist DMT) agonist Spencer et al.,

1987)

(Lejeune et al., 8-OH-DPAT 5-HT1A agonist 5-HT1A agonist 1997)

17--oestradiol oestrogen receptor agonist, (Kuiper et al., oestrogen agonist (alfatradiol) 5a-reductase inhibitor 1997)

(Kuiper et al., 17-beta-oestradiol oestrogen receptor agonist oestrogen agonist 1997)

(Vanover et al., A-66,359 D1 antagonist D1 antagonist 1991)

(Kebabian et al., A-77,636 D1 agonist D1 agonist 1992)

(Michaelides et

al., 1995; A-86,929 D1 agonist D1 agonist Ehrlich et al.,

1997)

(Marks et al., ABT-089 () b2 nACh agonist 2009)

2 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Malysz et al., ABT-107 a7 nACh agonist nicotinic agonist 2010)

(Zhang et al.,

ABT-126 (nelonicline) a7 nACh agonist nicotinic agonist 2015; Haig et

al., 2016)

(Shiosaki et al., ABT-431 (adrogolide) D1 agonist D1 agonist 1996)

ABT-894 (sofinicline) a4b2 nACh agonist nicotinic agonist (Ji et al., 2007)

(Koprich et al., ADL-5510 µ antagonist µ antagonist 2011)

AFQ-056 (Vranesic et al., mGlu5 NAM mGlu5 NAM (mavoglurant) 2014)

(Matsubayashi

NMDA antagonist, s1 et al., 1997;

agonist, a7 nACh NMDA antagonist Peeters et al.,

antagonist 2004; Blanpied

et al., 2005)

(Schlicker et al., anpirtoline 5-HT1B > 5-HT1A agonist 5-HT1B agonist 1992)

partial (Heinrich et al., (DAB-452) D2,3 partial agonist agonist 2006)

D1 agonist, D2,3,4 partial (Millan et al., agonist, 5-HT2A,2B, 2002; Newman-

3 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther

antagonist, 5-HT1A partial Tancredi et al.,

agonist, a2A partial agonist, 2002a;

a2B,2C antagonist Newman-

Tancredi et al.,

2002b)

nicotinic partial (Feuerbach et AQW-051 a7 nACh partial agonist agonist al., 2015)

muscarinic (Hirose et al., M1,2,3,4,5 antagonist antagonist 2001)

(Hirst et al., GABAB agonist GABAB agonist 2003)

benztropine M1,2 antagonist, DAT muscarinic (Newman et al.,

() inhibitor antagonist 1995)

(Bezard et al.,

BP-897 D3 partial agonist D3 partial agonist 2003; Pilleri and

Antonini, 2015)

non-selective (NS-2214, DAT, NET, SERT monoamine re- (Singh, 2000) BMS-204,756) inhibitor uptake inhibitor

D2,3-preferential dopamine

(CB- agonist, 5-HT1A,1D partial (Millan et al., dopamine agonist 154) agonist, a2A,2B,2C 2002)

antagonist

4 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther non-selective (Cheetham et DAT, NET, SERT BTS-74,398 monoamine re- al., 1998; Singh, inhibitor uptake inhibitor 2000)

(Carroll et al., dual monoamine DAT, NET inhibitor 2009; Lapinsky re-uptake inhibitor et al., 2009)

D2,3 partial agonist, 5- (Millan et al., HT1A,1D,2A,2B agonist, dopamine agonist 2002) a2A,2C antagonist

cannabinoid (Cao et al., CE CB1 antagonist antagonist 2007)

(Ben-Daniel et SERT inhibitor SERT inhibitor al., 2008)

(Barton and CI-1041 (, White, 2004; PD-196,860, Co- NR2B antagonist NMDA antagonist Barton et al., 200,461) 2004)

(Ernsberger et

a2A,2B,2C agonist, I1 agonist a2 agonist al., 1987; Jasper

et al., 1998)

H1 antagonist, 5- (Lahti et al., atypical anti- HT2A,2B,2C,6,7 antagonist, 1993; Schotte et psychotic a1A,1B,1D antagonist, D4 al., 1996;

5 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther

antagonist, 5-HT1A,1F Yoshio et al.,

agonist 2001; Booth et

al., 2002; Knight

et al., 2004;

Purohit et al.,

2005)

D2 fast-off (Koprich et al., CLR-151 D2 antagonist antagonist 2013)

Co-101,244/PD- (Gill et al., NR2B antagonist NMDA antagonist 174,494 (Ro-631,908) 2002)

(Koe et al., CP-94,253 5-HT1B-preferential agonist 5-HT1B agonist 1992)

(Chenard et al.,

CP-101,606 1995; NR2B antagonist NMDA antagonist () Brimecombe et

al., 1997)

(Feng et al., CPP NR2A,2B,2C,2D antagonist NMDA antagonist 2004)

(Krintel et al., CX-516 (BDP-12) GluA2 PAM 2013)

(Andersen and CY-208,243 D1,2 agonist dopamine agonist Jansen, 1990)

6 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther

5-HT2A,2C,6,7 antagonist, H1 (Leysen et al.,

antagonist, a1B,1D 5-HT antagonist 1981; Hoyer et

antagonist al., 1994)

(Bergeron et al.,

receptor agonist, 1996; Maurice

a- and b-oestrogen et al., 1997;

DHEA receptor agonist, GABAA androgen agonist Sousa and

NAM, NMDA PAM, s1 Ticku, 1997;

agonist Chen et al.,

2005)

(Pritchett et al., diazepam GABAA PAM GABAA PAM 1989)

dipraglurant (ADX- (Chae et al., mGlu5 NAM mGlu5 NAM 48,621) 2013)

(Lampen et al.,

2001; Itoh et al., FFA1 agonist, RXR-a docosahexaenoic acid RXR agonist 2003; Motter agonist, TRPA1 agonist and Ahern,

2012)

(DU- 5-HT1A,1B agonist, 5-HT2C (Schipper et al., 5-HT1A,1B agonist 28,853) antagonist 1990)

(Lotta et al., (OR-611) COMT inhibitor COMT inhibitor 1995)

7 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther T-type channel T-type calcium (Gomora et al., antagonist channel antagonist 2001)

(Newman- preferential post-synaptic F-15,599 5-HT1A agonist Tancredi et al., 5-HT1A agonist 2009)

famotidine H2 antagonist H2 antagonist (Chremos, 1987)

(Porter et al., fenobam mGlu5 NAM mGlu5 NAM 2005)

(Johnston et al., fipamezole (JP-1730) a2A,2B,2C antagonist a2 antagonist 2010)

GBR-12,909 (Andersen, DAT inhibitor DAT inhibitor () 1989)

(Abraham et al., GYKI-47,261 AMPA antagonist AMPA antagonist 2000)

(Sunahara et al.,

D2-like antagonist, D1 1991; Tice et al.,

antagonist, a1 antagonist, D2 antagonist 1994; Kroeze et

s1 antagonist al., 2003; Cobos

et al., 2007)

(Doxey et al.,

1984; a2 antagonist, I2 agonist a2 antagonist Regunathan and

Reis, 1996)

8 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Schlesinger et IEM-1460 AMPA antagonist AMPA antagonist al., 2005)

(Reynolds and

Miller, 1989; NR1,2 antagonist NMDA antagonist Korinek et al.,

2011)

(Garbarg et al.,

imetit H3,4 agonist H3,4 agonist 1992; Liu et al.,

2001)

(Liu et al., 2001;

immepip H3,4 agonist H3,4 agonist Kitbunnadaj et

al., 2003)

(KW- (Fredholm et al., A2A antagonist A2A antagonist 6002) 2011)

(Kawamoto et

J-113,397 ORL-1 antagonist ORL-1 antagonist al., 1999; Ozaki

et al., 2000)

dopamine (Liegeois et al., JL-18 D2,4 antagonist antagonist 1995)

(Philippens et JNJ-27,063,699 a2C antagonist a2 antagonist al., 2014)

(Patel et al., L-745,870 D4 antagonist D4 antagonist 1997)

9 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Fernstrom, L- 5-HT precursor 5-HT agonist 1983)

(Lynch et al., SV2A antagonist SV2A antagonist 2004)

(Tsuruta et al., LY-141,865 D2 agonist D2 agonist 1981)

(Schoepp et al., LY-235,959 (active NMDA antagonist NMDA antagonist 1991; Herman et isomer of LY-274,614) al., 1995)

NR2A-preferential (Blanchet et al., MDL-100,453 NMDA antagonist antagonist 1999)

(Battaglia et al.,

DAT inhibitor, SERT 1988; Nash et dual monoamine MDMA inhibitor, 5-HT2A partial al., 1994; re-uptake inhibitor agonist Verrico et al.,

2007)

melanocyte-inhibiting

factor (Pro-Leu-Gly- (Verma et al., NH2, melanostatin, D2,4 PAM, opiate D2 PAM 2005; Pan and MSH release- antagonist Kastin, 2007) inhibiting hormone,

MIF-1)

10 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Poulain et al., meperidine () µ > k > d agonist agonist 2001)

(Leysen et al.,

1981; Hoyer et

5-HT1D,1F,2A,2C antagonist, al., 1994; 5-HT antagonist 5-HT2B agonist Bonhaus et al.,

1997; Rothman

et al., 2000)

(Hyttel, 1982;

de Boer et al.,

5-HT2A,2C,3 antagonist, 1988; Hyttel, atypical anti- a1,2A,2C antagonist, H1 1994; Kooyman antagonist et al., 1994;

Fernandez et al.,

2005)

(de Boer, 1996;

Tatsumi et al., a2A,2C antagonist, 5- (ORG- atypical anti- 1997; Anttila HT2A,2C,3 antagonist, H1 3770) depressant and Leinonen, antagonist 2001; Fernandez

et al., 2005)

NMDA antagonist, a7 (Amador and MK-801 () NMDA antagonist nACh antagonist Dani, 1991)

11 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther T-type T-type calcium (Xiang et al., ML-218 antagonist channel antagonist 2011)

(Seeman et al., D2 partial agonist, DAT non-selective DAT 2009; inhibitor – not fully inhibitor Zolkowska et characterised al., 2009)

(Poulain et al., µ > k > d agonist opioid agonist 2001)

(Gasparini et al.,

MPEP mGlu5 NAM, mGlu4 PAM mGlu5 NAM 1999; Mathiesen

et al., 2003)

(Cosford et al., MTEP mGlu5 NAM mGlu5 NAM 2003)

(Van der Weide

et al., 1986; Van N-0437 D2-like agonist D2 agonist der Weide et al.,

1988)

(Dowling and

Charlton, 2006; muscarinic N-methyl M1,3 antagonist Fruchart- antagonist Gaillard et al.,

2006)

12 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther cannabinoid (Blaazer et al., CB1,2 agonist agonist 2011)

(Sautel et al.,

D2,3 antagonist, 5-HT1A dopamine 1995; Newman- agonist antagonist Tancredi et al.,

1998)

(Poulain et al., µ > k > d agonist opioid agonist 2001)

(Poulain et al., µ = k > d antagonist opioid antagonist 2001)

(Emmerson et

al., 1994; µ > k > d antagonist opioid antagonist Koprich et al.,

2011)

(Portoghese et naltrindole d > µ = k antagonist opioid antagonist al., 1988)

AMPA > kainate (Sheardown et NBQX AMPA antagonist antagonist al., 1990)

(Kavitha et al., neostigmine AChE inhibitor ChE inhibitor 2007)

non-selective nACh (Benowitz, nicotinic agonist agonist 2009)

13 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Wong et al., (LY-94,939) NET inhibitor NET inhibitor 1982)

(Andersen et al.,

1992; Nielsen NNC-01-112 D1 antagonist D1 antagonist and Andersen,

1992)

(Richelson and

Nelson, 1984; (HOE- dual monoamine DAT = NET inhibitor, Close et al., 984) re-uptake inhibitor 1990; Tatsumi et

al., 1997)

(Jakubik et al., oxotremorine M1,2,3,4 agonist 1997)

PAMQX (CGP- NMDA antagonist (at (Ametamey et NMDA antagonist 78,608) site) al., 2000)

(Glennon et al., (SLV- D2,3 partial agonist, 5-HT1A dopamine partial 2006; Jones et 308) agonist agonist al., 2010)

(DeWald et al.,

1990; Akunne et

PD-128,907 D2,3 agonist dopamine agonist al., 1995;

Pugsley et al.,

1995)

14 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther

5-HT1A,1D partial agonist,

5-HT2A,2B agonist, D2 (LY- (Millan et al., agonist, D3,4 partial dopamine agonist 127,809) 2002) agonist, a2A,2B,2C partial

agonist

AChE inhibitor, BuChE (Luo et al., physostigmine ChE inhibitor inhibitor 2006)

(ACP- 5-HT2A inverse (Vanover et al., 5-HT2A,2C inverse agonist 103) agonist 2006)

(Smith, 2001; PPARg > a agonist, pioglitazone PPARg agonist Paddock et al., mitoNEET ligand 2007)

a1A,2A,2C antagonist, D2,3

partial agonist, D4 (Millan et al., dopamine agonist antagonist, 5-HT1A partial 2002)

agonist

lipid plasmalogen plasmalogen (Wood et al., PPI-1011 precursor precursor 2011)

(Newman- D2S agonist, D2L,3,4 partial dopamine agonist Tancredi et al., agonist 2002a)

(Ford et al., a1A,1B,1C antagonist a1 antagonist 1997)

15 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (SCH- (Hodgson et al., A2A antagonist A2A antagonist 420,814) 2009)

(Rupprecht et

al., 1993;

Falkenstein et

al., 1998; Meyer

et al., 1998a;

Meyer et al., nPR agonist, mPR agonist, 1998b; Baulieu PGRMC1 agonist, s1 PR agonist and agonist, nACh NAM, MR Schumacher, antagonist 2000; Maurice

et al., 2001;

Attardi et al.,

2007;

Johannessen et

al., 2011)

b1,2 antagonist b antagonist (Baker, 2005)

H1 antagonist, D2 (Schotte et al., antagonist, 5-HT2A atypical anti- 1996; Arnt and antagonist, 5-HT1A,1B psychotic Skarsfeldt, agonist, a1A,1B,2C 1998; Richelson antagonist

16 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther and Souder,

2000)

(LY- (Millan et al., D2-like agonist D2 agonist 171,555) 2002)

R-(-)-11-OH-NPa (Neumeyer et (apomorphine D1,2 agonist D1,2 agonist al., 1988) derivative)

(Lejeune et al., (R)-(+)-OHDPAT 5-HT1A agonist 5-HT1A agonist 1997)

(Lyon et al.,

1986; Battaglia

et al., 1988; 5-HT2A partial R-MDMA 5-HT2A partial agonist Nash et al., agonist 1994; Verrico et

al., 2007; Huot

et al., 2011)

(Wichmann et D2,3 antagonist D2,3 antagonist al., 1999)

(Weinshank et (iso- al., 1992; Uhlen , a- a2A,2B,2C antagonist, 5- a2 antagonist et al., 1994; yohimbine, HT1D,2D antagonist Wainscott et al., corynanthidine) 1998)

17 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Subramaniam

NMDA antagonist, Na+ et al., 1996; NMDA antagonist Santangeli et al.,

2002)

RGFP-109 HDAC1,3 inhibitor HDAC inhibitor (Rai et al., 2010)

(SR- cannabinoid (Seely et al., CB1 antagonist 141,716) antagonist 2012)

(Fischer et al., Ro-25,6981 NR2B antagonist NMDA antagonist 1997)

3- kynurenine 3-hydroxylase (Rover et al., Ro-61,8048 hydroxylase inhibitor 1997) inhibitor

(Wichmann et NOP receptor agonist, µ > Ro 65-6570 opioid ligand al., 1999; Toll et k > d ligand al., 2016)

(Eden et al.,

(SKF- 1991; Millan et D2,3,4 agonist dopamine agonist 101,468-A) al., 2002; Millan

et al., 2004b)

D1,2,3,4,5 agonist, a1A,B (Beaulieu et al., (N-0427, N- ligand, a2A,2B,2C ligand, 5- dopamine agonist 1984; Belluzzi 0923) HT1A partial agonist, 5- et al., 1994; HT7 ligand

18 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Scheller et al.,

2009)

(Millan et al.,

S-32,504 D2,3 agonist dopamine agonist 2004a; Millan et

al., 2004b)

(Cussac et al.,

S-33,084 D3 antagonist D3 antagonist 2000; Millan et

al., 2000a)

(Verrico et al., SERT > DAT inhibitor, dual monoamine S-MDMA 2007; Huot et monoamine releaser re-uptake inhibitor al., 2011)

NET > DAT inhibitor, dual monoamine (Damaj et al., S,S- a4b2 nACh antagonist re-uptake inhibitor 2004)

MAO-B inhibitor, (Caccia et al.,

glutamate release inhibitor, MAO-B inhibitor 2006; Fariello,

Na+ channel blocker 2007)

(EMD- 5-HT1A agonist, D2,3,4 (Bartoszyk et 5-HT1A agonist 128,130) antagonist al., 2004)

5-HT1B inverse (Selkirk et al., SB-224,289-A 5-HT1B inverse agonist agonist 1998)

D1 antagonist, 5-HT2C (Millan et al., SCH-23,390 D1 antagonist agonist 2001)

19 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther scopolamine muscarinic (Huang et al., M1,2,3,4 antagonist (hyoscine) antagonist 2001)

(Owens et al., SERT inhibitor SERT inhibitor 2001)

HMG-CoA reductase HMG-CoA (Hartman et al., simvastatin inhibitor reductase inhibitor 1992)

(Andersen and

Jansen, 1990; SKF-38,393 D1,5 partial agonist D1 partial agonist Sunahara et al.,

1991)

(Andersen and

Jansen, 1990; SKF-75,670 D1 partial agonist D1 partial agonist Gnanalingham

et al., 1995)

(Gnanalingham

et al., 1995; SKF-80,723 D1 agonist D1 agonist Kanda et al.,

2000)

(Gnanalingham

et al., 1995; D1 agonist, oestrogen SKF-82,958 D1 agonist Domino and Ni, receptor-a agonist 1998; Walters et

al., 2002)

20 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Gnanalingham SKF-83,565 D1 partial agonist D1 partial agonist et al., 1995)

(Gnanalingham D1 agonist, D2 partial et al., 1995; agonist, s1 allosteric Rashid et al., SKF-83,959 ligand, DAT inhibitor, D1 agonist 2007; Fang et NET inhibitor, SERT al., 2013; Guo et inhibitor al., 2013)

5-HT1B,1D > 5-HT1A (Hatcher et al., SKF-99,101-H 5-HT1B,1D agonist agonist 1995)

(Bilsky et al.,

SNC-80 d agonist d agonist 1995; Metcalf et

al., 2012)

(Bezard et al., ST-198 D3 antagonist D3 antagonist 2003)

(Stasi et al., ST-1535 A2A > A1 antagonist A2A antagonist 2006)

(Maitre et al., D2,3 antagonist, carbonic 1994; Burris et anhydrase inhibitor, GHB D2,3 antagonist al., 1995; Sethi ligand et al., 2013)

(PNU- (McCall et al., D2 agonist D2 agonist 95,666) 2005)

21 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (GYKI- (Wang and Niu, GluA2 antagonist AMPA antagonist 537,773, LY-300,164) 2013)

oestrogen receptor a and b oestrogen receptor (Kuiper et al., tamoxifen modulator modulator 1997)

(Johnston et al.,

TC-8831 b2 nACh agonist nicotinic agonist 2013; Quik et

al., 2013)

a1A,2A,2B,2C antagonist, D2,3

partial agonist, D4 (trans- (Millan et al., antagonist, 5-HT1A,1D,2A D2 partial agonist dihydro-) 2002) partial agonist, 5-HT2B

antagonist

Na+ channel blocker,

GABAA enhancer, AMPA AMPA antagonist (Perucca, 1997) antagonist, carbonic

anhydrase inhibitor

muscarinic (Giachetti et al., M1 antagonist antagonist 1986)

(Von

U50-488 k agonist opioid agonist Voigtlander and

Lewis, 1982)

(Black et al., U-91,356-A D2 agonist D2 agonist 1997)

22 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther U-99,194-A (PNU- (Audinot et al., D3 antagonist D3 antagonist 99,194-A) 1998)

(Mor et al., URB-597 (KDS-4103) FAAH inhibitor FAAH inhibitor 2004)

UWA-101 (a- dual monoamine (Johnston et al., DAT = SERT inhibitor cyclopropyl-MDMA) re-uptake inhibitor 2012)

dual monoamine (Huot et al., UWA-121 DAT > SERT inhibitor re-uptake inhibitor 2014)

(Huot et al., UWA-122 SERT inhibitor SERT inhibitor 2014)

non-selective nACh (Mihalak et al., nicotinic agonist agonist/partial agonist 2006)

(Shen et al., VU-0,476,406 M4 PAM muscarinic PAM 2015)

(Bylund et al.,

1992; Adham et

al., 1993;

a2A,2B,2C antagonist, 5- Devedjian et al., yohimbine a2 antagonist HT1A,1B,1D,1F,2B antagonist 1994; Bonhaus

et al., 1999;

Millan et al.,

2000b)

23 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther 5-HT: 5-hydroxytryptamine (); a: alpha adrenoceptor (except when followed by nACh, where they correspond to a sub-unit); b: beta adrenoceptor (except when followed by nACh, where they correspond to a sub-unit); d: delta opioid receptor; k opioid receptor; µ opiod receptor; s: sigma receptor; A: receptor; AChE: acetylcholinesterase; AMPA: α- amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BuChE: butyrylcholinesterase;

CB: cannabinoid receptor; ChE: ; COMT: catechol-O-methyltransferase; D: ; DAT: ; FAAH: fatty acid amide hydrolase; FFA: free fatty acid receptor; GABA: gamma-aminobutyric acid; GHB: gamma-hydroxybutyric acid;

GluA: AMPA receptor sub-unit; H: histamine receptor; HDAC: histone deacetylase; HMG-CoA:

3-hydroxy-3-methylglutaryl-coenzyme A; I: ; M: muscarinic receptor;

MAO-B: ; MDMA: 3,4-methylenedioxymethamphetamine; mGlu: metabotropic ; MPR: membrane progesterone receptor; MR: mineralocorticoid receptor; Na+: ; nACh: nicotinic receptor; NAM: negative ; NET: noradrenaline transporter; NMDA: N-methyl-D-aspartate; NOP: nociceptin receptor; NPR: natriuretic peptide receptor; NR: NMDA receptor sub-unit; ORL: opioid receptor- like; PAM: positive allosteric modulator; PGRMC1: progesterone receptor membrane component

1; PPAR: peroxisome proliferator-activated receptor; PR: progesterone receptor; RXR: retinoid X receptor; SERT: ; SV: synaptic vesicle glycoprotein; TRPA: transient receptor potential channel ankyrin.

24 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Table S2: comparison of the anti-dyskinetic action of drugs across species

marmose drug human macaque squirrel monkey t

(+)-4-propyl-9-

hydroxynaphth ne na ne na

oxazine

ABT-431 ne ne ne na

AFQ-056 Ö/ne Ö na na

amantadine Ö Ö Ö na

apomorphine ne ne ne na

AQW051 ne Ö na na

atropine ne ne ne na

benztropine ne na ne na

brasofensine ne na ne na

bromocriptine ne ne ne na

bupropion ne na ne na

cabergoline ne ne na na

citalopram Ö Ö na na

clonidine na Ö na na

clozapine Ö Ö Ö na

CP-101,606 Ö ne ne na

25 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther CY-208,243 ne ne ne na

diazepam Ö Ö na na

dipraglurant Ö Ö na na

eltoprazine Ö Ö na na

entacapone de ne ne na

ethosuximide ne ne na na

famotidine ne Ö na na

fipamezole Ö Ö Ö na

haloperidol Ö na Ö na

idazoxan Ö/ne Ö Ö na

istradefylline ne ne ne na

L-tryptophan na Ö na ne

levetiracetam Ö/ne Ö Ö na

melanocyte- ne na ne na inhibiting factor

methysergide ne Ö na na

mianserin na na Ö na

mirtazapine Ö na Ö na

modafinil ne na na na

morphine Ö Ö na na

nabilone Ö na Ö na

naloxone Ö/ne Ö na na

26 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther naltrexone Ö/ne ne/de Ö na

nicotine na na na Ö

nomifensine de na ne na

pardoprunox ne na Ö na

pergolide ne na ne na

physostigmine Ö/ne Ö ne na

pimavanserin ne Ö na na

pioglitazone ne Ö na na

piribedil ne na ne na

pramipexole ne na ne na

preladenant de ne na na

propranolol Ö Ö na na

quetiapine Ö/ne Ö Ö na

remacemide ne ne na na

ropinirole ne na ne na

rotigotine ne ne ne na

safinamide Ö Ö na na

sarizotan ne Ö na na

scopolamine ne na ne na

sertraline ne na na na

simvastatin ne Ö na na

sulpiride Ö Ö ne na

27 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther sumanirole ne ne na na

terguride ne ne ne na

topiramate de/ne na Ö na

trihexyphenidyl ne ne ne na

yohimbine na Ö Ö na

Ö: effective; ne: not effective; de: deleterious; na: not assessed

28 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Table S3: comparison of the anti-parkinsonian action of drugs across species

marmose drug human macaque squirrel monkey t

(+)-4-propyl-9-

hydroxynaphth Ö na Ö na

oxazine

ABT-431 Ö Ö Ö na

AFQ-056 ne Ö na na

amantadine Ö/ne ne/de ne na

apomorphine Ö Ö Ö na

AQW-051 ne Ö na na

atropine Ö Ö Ö na

benztropine Ö na Ö na

brasofensine ne na Ö na

bromocriptine Ö Ö Ö na

bupropion Ö na Ö na

cabergoline Ö Ö na na

citalopram Ö/ne de na na

clonidine Ö Ö/de na na

clozapine Ö ne ne na

CP-101,606 ne Ö Ö na

29 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther CY-208,243 Ö Ö Ö na

diazepam Ö ne na na

dipraglurant ne ne na na

eltoprazine ne de na na

entacapone Ö Ö Ö na

ethosuximide ne/de Ö na na

famotidine ne Ö na na

fipamezole ne Ö Ö na

haloperidol de na de na

idazoxan ne Ö Ö na

istradefylline Ö Ö Ö na

L-tryptophan ne de na na

levetiracetam ne ne ne na

melanocyte- ne na ne na inhibiting factor

methysergide ne de na na

mianserin na na de na

mirtazapine Ö na ne na

modafinil ne na Ö na

morphine de Ö na na

nabilone ne na ne na

naloxone Ö/ne ne na na

30 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther naltrexone ne ne ne na

nicotine Ö/ne na na ne

nomifensine Ö na Ö na

pardoprunox Ö na Ö na

pergolide Ö na Ö na

physostigmine de de de na

pimavanserin ne ne na na

pioglitazone ne de na na

piribedil Ö na Ö na

pramipexole Ö na Ö na

preladenant Ö Ö na na

propranolol Ö/ne de na na

quetiapine ne/de ne ne na

remacemide ne Ö na na

ropinirole Ö na Ö na

rotigotine Ö Ö Ö na

safinamide Ö Ö na na

sarizotan de de na na

scopolamine Ö na Ö na

sertraline ne na de na

simvastatin ne ne na na

sulpiride de de de na

31 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther sumanirole Ö Ö na na

terguride Ö Ö Ö na

topiramate ne na ne na

trihexyphenidyl Ö Ö Ö na

yohimbine Ö ne ne na

Ö: effective; ne: not effective; de: deleterious; na: not assessed

32 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Supplementary references

Abraham G, Solyom S, Csuzdi E, Berzsenyi P, Ling I, Tarnawa I, Hamori T, Pallagi I, Horvath K,

Andrasi F, Kapus G, Harsing LG, Jr., Kiraly I, Patthy M and Horvath G (2000) New non

competitive AMPA antagonists. Bioorg Med Chem 8:2127-2143.

Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank

RL and Branchek TA (1993) Cloning of another human serotonin receptor (5-HT1F): a

fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad

Sci U S A 90:408-412.

Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikstrom H, Heffner TG, Wise LD and Pugsley TA

(1995) Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor

agonist ligand, to CHO-K1 cells. Life Sci 57:1401-1410.

Amador M and Dani JA (1991) MK-801 inhibition of nicotinic channels.

Synapse 7:207-215.

Ametamey SM, Kokic M, Carrey-Remy N, Blauenstein P, Willmann M, Bischoff S, Schmutz M,

Schubiger PA and Auberson YP (2000) Synthesis, radiolabelling and biological

characterization of (D)-7-iodo-N-(1-phosphonoethyl)-5-aminomethylquinoxaline-2,3-

dione, a glycine-binding site antagonist of NMDA receptors. Bioorg Med Chem Lett 10:75-

78.

Andersen PH (1989) The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of

action. Eur J Pharmacol 166:493-504.

Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C and Nielsen EB

(1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1

receptor antagonists. Eur J Pharmacol 219:45-52.

33 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Andersen PH and Jansen JA (1990) Dopamine receptor : selectivity and dopamine D1

receptor efficacy. Eur J Pharmacol 188:335-347.

Anttila SA and Leinonen EV (2001) A review of the pharmacological and clinical profile of

mirtazapine. CNS Drug Rev 7:249-264.

Arnt J, Bogeso KP, Christensen AV, Hyttel J, Larsen JJ and Svendsen O (1983) Dopamine receptor

agonistic and antagonistic effects of 3-PPP . Psychopharmacology (Berl)

81:199-207.

Arnt J and Skarsfeldt T (1998) Do novel have similar pharmacological

characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.

Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN and Obstetric-Fetal

Pharmacology Research Unit N (2007) Comparison of progesterone and glucocorticoid

receptor binding and stimulation of gene expression by progesterone, 17-alpha

hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol 197:599 e591-

597.

Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte

I, Bervoets K, Dekeyne A and Millan MJ (1998) A comparative in vitro and in vivo

pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S

14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 287:187-197.

Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and

beta3 adrenoceptors. Br J Pharmacol 144:317-322.

Barton ME and White HS (2004) The effect of CGX-1007 and CI-1041, novel NMDA receptor

antagonists, on kindling acquisition and expression. Res 59:1-12.

Barton ME, White HS and Wilcox KS (2004) The effect of CGX-1007 and CI-1041, novel NMDA

receptor antagonists, on NMDA receptor-mediated EPSCs. Epilepsy Res 59:13-24.

34 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H and Seyfried CA (2004)

Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1.

Neurochemical profile. J Neural Transm 111:113-126.

Battaglia G, Brooks BP, Kulsakdinun C and De Souza EB (1988) Pharmacologic profile of MDMA

(3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J

Pharmacol 149:159-163.

Baulieu E and Schumacher M (2000) Progesterone as a neuroactive neurosteroid, with special

reference to the effect of progesterone on myelination. Steroids 65:605-612.

Beaulieu M, Itoh Y, Tepper P, Horn AS and Kebabian JW (1984) N,N-disubstituted 2-

aminotetralins are potent D-2 dopamine receptor agonists. Eur J Pharmacol 105:15-21.

Belluzzi JD, Domino EF, May JM, Bankiewicz KS and McAfee DA (1994) N-0923, a selective

dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's

disease. Mov Disord 9:147-154.

Ben-Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P and Mishani E (2008)

Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of

the serotonin transporter. Bioorg Med Chem 16:6364-6370.

Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and

therapeutics. Annu Rev Pharmacol Toxicol 49:57-71.

Bergeron R, de Montigny C and Debonnel G (1996) Potentiation of neuronal NMDA response

induced by and its suppression by progesterone: effects mediated

via sigma receptors. J Neurosci 16:1193-1202.

Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C and Sokoloff P (2003)

Attenuation of levodopa-induced by normalizing dopamine D3 receptor

function. Nat Med 9:762-767.

35 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, McNutt RW, Rothman RB,

Rice KC and Porreca F (1995) SNC 80, a selective, nonpeptidic and systemically active

opioid delta agonist. J Pharmacol Exp Ther 273:359-366.

Blaazer AR, Lange JH, van der Neut MA, Mulder A, den Boon FS, Werkman TR, Kruse CG and

Wadman WJ (2011) Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB)

receptor agonists: design, synthesis, structure-activity relationships, physicochemical

properties and biological activity. Eur J Med Chem 46:5086-5098.

Black KJ, Gado MH and Perlmutter JS (1997) PET measurement of dopamine D2 receptor-

mediated changes in striatopallidal function. J Neurosci 17:3168-3177.

Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM and Chase TN (1999)

Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on

in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J

Pharmacol Exp Ther 290:1034-1040.

Blanpied TA, Clarke RJ and Johnson JW (2005) Amantadine inhibits NMDA receptors by

accelerating channel closure during channel block. J Neurosci 25:3312-3322.

Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang

LK, Pulido-Rios T, Webber A, Leung E, Eglen RM and Martin GR (1999) RS-127445: a

selective, high affinity, orally bioavailable 5-HT2B . Br J Pharmacol

127:1075-1082.

Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ,

Trinh J, Rocha CL, Dawson MW, Flippin LA and Eglen RM (1997) RS-102221: a novel

high affinity and selective, 5-HT2C receptor antagonist. 36:621-629.

36 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H and Leurs R (2002) A

novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors.

J Pharmacol Exp Ther 302:328-336.

Brimecombe JC, Boeckman FA and Aizenman E (1997) Functional consequences of NR2 subunit

composition in single recombinant N-methyl-D-aspartate receptors. Proc Natl Acad Sci U

S A 94:11019-11024.

Burris KD, Pacheco MA, Filtz TM, Kung MP, Kung HF and Molinoff PB (1995) Lack of

discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology

12:335-345.

Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A and Hacksell U (2011) II.

In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects

through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm (Vienna)

118:1523-1533.

Bylund DB, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ and Lomasney JW (1992)

Pharmacological characteristics of alpha 2- receptors: comparison of

pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol

Pharmacol 42:1-5.

Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P and Fariello RG

(2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology

67:S18-23.

Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT and

Papa SM (2007) Blockade of cannabinoid type 1 receptors augments the antiparkinsonian

action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-

tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 323:318-326.

37 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M, Rung JP and Carlsson

A (2011) I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162

on 5-HT2A serotonin receptors. J Neural Transm (Vienna) 118:1511-1522.

Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, Decker AM,

Landavazo A, McElroy KT, Navarro HA, Gatch MB and Forster MJ (2009) Synthesis and

biological evaluation of bupropion analogues as potential pharmacotherapies for

addiction. J Med Chem 52:6768-6781.

Chae E, Shin YJ, Ryu EJ, Ji MK, Ryune Cho N, Lee KH, Jeong HJ, Kim SJ, Choi Y, Seok Oh K,

Park CE and Soo Yoon Y (2013) Discovery of biological evaluation of pyrazole/imidazole

amides as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett 23:2134-

2139.

Cheetham S, Butler S, Hearson M, Kerrigan F, Martin K, Needham P, Prow M, Sargent B, Slater

N and Skill M (1998) BTS 74 398: a novel monoamine for the treatment

of Parkinson's disease. Br J Pharmacol 123 Suppl 1:224P.

Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada

S, Freedman LP and Reszka AA (2005) Direct agonist/antagonist functions of

dehydroepiandrosterone. Endocrinology 146:4568-4576.

Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, Ducat MF, Dumont

ML, Fox CB, Mena EE and et al. (1995) (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-

phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-

aspartate responses. J Med Chem 38:3138-3145.

Chremos AN (1987) Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol 9

Suppl 2:7-12.

38 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Close SP, Elliott PJ, Hayes AG and Marriott AS (1990) Effects of classical and novel agents in a

MPTP-induced reversible model of Parkinson's disease. Psychopharmacology (Berl)

102:295-300.

Cobos EJ, del Pozo E and Baeyens JM (2007) Irreversible blockade of sigma-1 receptors by

haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma

cells. J Neurochem 102:812-825.

Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang

X, McDonald I, Rao S, Washburn M and Varney MA (2003) 3-[(2-Methyl-1,3-thiazol-4-

yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5

receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.

Cussac D, Newman-Tancredi A, Sezgin L and Millan MJ (2000) The novel antagonist, S33084,

and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as

compared with native, rat dopamine D(2) receptors. Eur J Pharmacol 394:47-50.

Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ and Martin BR

(2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on

function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675-682. de Boer T (1996) The pharmacologic profile of mirtazapine. J Clin Psychiatry 57 Suppl 4:19-25. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J and Pinder RM (1988) Neurochemical

and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and

its enantiomers. Neuropharmacology 27:399-408.

Devedjian JC, Esclapez F, Denis-Pouxviel C and Paris H (1994) Further characterization of human

alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional

selective drugs. Eur J Pharmacol 252:43-49.

39 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, Pugsley TA and

Wise LD (1990) Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-

tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. J

Med Chem 33:445-450.

Domino EF and Ni L (1998) Trihexyphenidyl interactions with the dopamine D1-selective receptor

agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-

1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther

284:307-311.

Dowling MR and Charlton SJ (2006) Quantifying the association and dissociation rates of

unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 148:927-937.

Doxey JC, Lane AC, Roach AG and Virdee NK (1984) Comparison of the alpha-adrenoceptor

antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and .

Naunyn Schmiedebergs Arch Pharmacol 325:136-144.

Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, Naylor RJ, Owen DA and

Wright A (1991) Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel

dopamine D2 agonist. Pharmacol Biochem Behav 38:147-154.

Ehrlich PP, Ralston JW and Michaelides MR (1997) An Efficient Enantioselective Synthesis of

the D1 Agonist (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia- 5-

azacyclopenta[c]phenanthrene-9,10-diol (A-86929). J Org Chem 62:2782-2785.

Emmerson PJ, Liu MR, Woods JH and Medzihradsky F (1994) Binding affinity and selectivity of

at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp

Ther 271:1630-1637.

Ernsberger P, Meeley MP, Mann JJ and Reis DJ (1987) Clonidine binds to imidazole binding sites

as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 134:1-13.

40 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Falkenstein E, Schmieding K, Lange A, Meyer C, Gerdes D, Welsch U and Wehling M (1998)

Localization of a putative progesterone membrane binding protein in porcine hepatocytes.

Cell Mol Biol (Noisy-le-grand) 44:571-578.

Fang X, Guo L, Jia J, Jin GZ, Zhao B, Zheng YY, Li JQ, Zhang A and Zhen XC (2013) SKF83959

is a novel triple reuptake inhibitor that elicits anti-depressant activity. Acta Pharmacol Sin

34:1149-1155.

Fariello RG (2007) Safinamide. Neurotherapeutics 4:110-116.

Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL and Mitchell RL

(1995) Comparison of the pharmacology and signal transduction of the human cannabinoid

CB1 and CB2 receptors. Mol Pharmacol 48:443-450.

Feng B, Tse HW, Skifter DA, Morley R, Jane DE and Monaghan DT (2004) Structure-activity

analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-

2-carbonyl) -2,3-dicarboxylic acid. Br J Pharmacol 141:508-516.

Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK and

Trabanco AA (2005) Discovery of new tetracyclic tetrahydrofuran derivatives as potential

broad-spectrum psychotropic agents. J Med Chem 48:1709-1712.

Fernstrom JD (1983) Role of precursor availability in control of monoamine biosynthesis in brain.

Physiol Rev 63:484-546.

Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G,

Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T and Lopez Lopez C

(2015) AQW051, a novel, potent and selective alpha7 nicotinic ACh receptor partial

agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol

172:1292-1304.

41 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP and Kemp JA (1997)

Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors

containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-

1292.

Ford AP, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD and Clarke DE (1997)

Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor:

implications for alpha1-adrenoceptor classification. Br J Pharmacol 121:1127-1135.

Fredholm BB, AP IJ, Jacobson KA, Linden J and Muller CE (2011) International Union of Basic

and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine

receptors--an update. Pharmacol Rev 63:1-34.

Fruchart-Gaillard C, Mourier G, Marquer C, Menez A and Servent D (2006) Identification of

various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized

muscarinic toxin 7. Mol Pharmacol 69:1641-1651.

Garbarg M, Arrang JM, Rouleau A, Ligneau X, Tuong MD, Schwartz JC and Ganellin CR (1992)

S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor

agonist. J Pharmacol Exp Ther 263:304-310.

Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H,

Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori

EM, Velicelebi G and Kuhn R (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a

potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology

38:1493-1503.

Giachetti A, Giraldo E, Ladinsky H and Montagna E (1986) Binding and functional profiles of the

selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J

Pharmacol 89:83-90.

42 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Gill R, A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez

HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht

R, Wyler R and Kemp JA (2002) Pharmacological characterization of Ro 63-1908 (1-[2-

(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-

selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 302:940-948.

Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long

SK, Feenstra RW and McCreary AC (2006) In vitro characterization of SLV308 (7-[4-

methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial

dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse

60:599-608.

Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P and Marsden CD (1995) Differential

anti-parkinsonian effects of D1 dopamine agonists with varying efficacies in

the MPTP-treated common marmoset. Psychopharmacology (Berl) 117:275-286.

Gomora JC, Daud AN, Weiergraber M and Perez-Reyes E (2001) Block of cloned human T-type

calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 60:1121-1132.

Gower AJ and Marriott AS (1982) Pharmacological evidence for the subclassification of central

dopamine receptors in the rat. Br J Pharmacol 77:185-193.

Guo L, Zhao J, Jin G, Zhao B, Wang G, Zhang A and Zhen X (2013) SKF83959 is a potent

allosteric modulator of sigma-1 receptor. Mol Pharmacol 83:577-586.

Haig G, Wang D, Othman AA and Zhao J (2016) The alpha7 Nicotinic Agonist ABT-126 in the

Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results

from a Randomized Controlled Phase 2b Study. Neuropsychopharmacology 41:2893-2902.

Hartman GD, Halczenko W, Duggan ME, Imagire JS, Smith RL, Pitzenberger SM, Fitzpatrick SL,

Alberts AW, Bostedor R, Chao YS and et al. (1992) 3-Hydroxy-3-methylglutaryl-

43 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel

simvastatin analogs. J Med Chem 35:3813-3821.

Hatcher JP, Slade PD, Roberts C and Hagan JJ (1995) 5-HT 1D receptors mediate SKF 99101H-

induced hypothermia in the guinea pig. J Psychopharmacol 9:234-241.

Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack

G, Marquis KL and Andree TH (2006) Aplindore (DAB-452), a high affinity selective

dopamine D2 receptor partial agonist. Eur J Pharmacol 552:36-45.

Herman BH, Vocci F and Bridge P (1995) The effects of NMDA receptor antagonists and nitric

oxide synthase inhibitors on opioid tolerance and withdrawal. development

issues for opiate addiction. Neuropsychopharmacology 13:269-293.

Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K, Sato A, Hasegawa T, Nishikibe

M, Mitsuya M, Ohtake N, Mase T and Noguchi K (2001) Pharmacological properties of

(2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopen tyl]-

2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing

antagonistic activity. J Pharmacol Exp Ther 297:790-797.

Hirst WD, Babbs AJ, Green A, Minton JA, Shaw TE, Wise A, Rice SQ, Pangalos MN and Price

GW (2003) Pharmacological characterisation of a cell line expressing GABA B1b and

GABA B2 receptor subunits. Biochem Pharmacol 65:1103-1113.

Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, Cohen-Williams ME,

Higgins GA, Impagnatiello F, Nicolussi E, Parra LE, Foster C, Zhai Y, Neustadt BR,

Stamford AW, Parker EM, Reggiani A and Hunter JC (2009) Characterization of the potent

and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-

difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e ][1,2,4]triazolo[1,5-

44 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther c]pyrimidin-5-amine] in rodent models of movement disorders and . J

Pharmacol Exp Ther 330:294-303.

Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR and

Humphrey PP (1994) International Union of Pharmacology classification of receptors for

5-hydroxytryptamine (Serotonin). Pharmacol Rev 46:157-203.

Huang F, Buchwald P, Browne CE, Farag HH, Wu WM, Ji F, Hochhaus G and Bodor N (2001)

Receptor binding studies of soft agents. AAPS PharmSci 3:E30.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ and Brotchie JM

(2011) Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers

In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia,

Whereas S-MDMA Extends Duration of ON-Time. J Neurosci 31:7190-7198.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ and Brotchie JM

(2014) UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA

anti-parkinsonian action without worsening dyskinesia or -like behaviours in the

MPTP-lesioned common marmoset. Neuropharmacology 82:76-87.

Hyttel J (1982) Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with

activity. Prog Neuropsychopharmacol Biol Psychiatry 6:277-295.

Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors

(SSRIs). Int Clin Psychopharmacol 9 Suppl 1:19-26.

Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka

Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H,

Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y and Fujino M (2003) Free

fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature

422:173-176.

45 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Iyengar S, Wood PL, Mick SJ, Dilworth VM, Gray NM, Farah JM, Rao TS and Contreras PC

(1991) (+) 3-[3-hydroxyphenyl-N-(1-propyl) piperidine] selectively differentiates effects

of sigma ligands on neurochemical pathways modulated by sigma receptors: evidence for

subtypes, in vivo. Neuropharmacology 30:915-922.

Jakubik J, Bacakova L, El-Fakahany EE and Tucek S (1997) Positive cooperativity of acetylcholine

and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol

Pharmacol 52:172-179.

Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SA, Daunt DA, Bonhaus DW

and Eglen RM (1998) Ligand efficacy and at recombinant alpha2 adrenergic

receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol 55:1035-

1043.

Ji J, Schrimpf MR, Sippy KB, Bunnelle WH, Li T, Anderson DJ, Faltynek C, Surowy CS, Dyhring

T, Ahring PK and Meyer MD (2007) Synthesis and structure-activity relationship studies

of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor

selective agonists. J Med Chem 50:5493-5508.

Johannessen M, Fontanilla D, Mavlyutov T, Ruoho AE and Jackson MB (2011) Antagonist action

of progesterone at sigma-receptors in the modulation of voltage-gated sodium channels. Am

J Physiol Cell Physiol 300:C328-337.

Johnston TH, Fox SH, Piggott MJ, Savola JM and Brotchie JM (2010) The alpha adrenergic

antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov

Disord 25:2084-2093.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR,

Jordan KG, Hill MP and Brotchie JM (2013) TC-8831, a nicotinic acetylcholine receptor

46 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology

73C:337-347.

Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN,

McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE,

Piggott MJ and Brotchie JM (2012) A novel MDMA analogue, UWA-101, that lacks

psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.

FASEB J 26:2154-2163.

Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG and

McCreary AC (2010) An in vivo pharmacological evaluation of pardoprunox (SLV308)--a

novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor

agonist with efficacy in experimental models of Parkinson's disease. Eur

Neuropsychopharmacol 20:582-593.

Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y and Jenner P (2000)

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective

D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in

MPTP-treated monkeys. Exp Neurol 162:321-327.

Kavitha CV, Gaonkar SL, Narendra Sharath Chandra JN, Sadashiva CT and Rangappa KS (2007)

Synthesis and screening for acetylcholinesterase inhibitor activity of some novel 2-butyl-

1,3-diaza-spiro[4,4]non-1-en-4-ones: derivatives of irbesartan key intermediate. Bioorg

Med Chem 15:7391-7398.

Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H and Iwasawa Y

(1999) Discovery of the first potent and selective small molecule opioid receptor-like

(ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-

ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 42:5061-5063.

47 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R and Williams

M (1992) A-77636: a potent and selective dopamine D1 receptor agonist with

antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209.

Kitbunnadaj R, Zuiderveld OP, De Esch IJ, Vollinga RC, Bakker R, Lutz M, Spek AL, Cavoy E,

Deltent MF, Menge WM, Timmerman H and Leurs R (2003) Synthesis and structure-

activity relationships of conformationally constrained histamine H(3) receptor agonists. J

Med Chem 46:5445-5457.

Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G and Bickerdike M (2004)

Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-

HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370:114-123.

Koe BK, Nielsen JA, Macor JE and Heym J (1992) Biochemical and behavioral studies of the 5-

HT1B receptor agonist, CP-94,253. Drug Dev Res 26:241-250.

Kooyman AR, Zwart R, Vanderheijden PM, Van Hooft JA and Vijverberg HP (1994) Interaction

between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse

neuroblastoma cells. Neuropharmacology 33:501-507.

Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, Dehaven RN,

Dehaven-Hudkins DL, Little PJ and Brotchie JM (2011) The selective mu-opioid receptor

antagonist adl5510 reduces levodopa-induced dyskinesia without affecting

antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease. Mov

Disord 26:1225-1233.

Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P and Brotchie JM (2013) The effects

of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in

parkinsonian macaques. Prog Neuropsychopharmacol Biol Psychiatry 43:151-156.

48 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Korinek M, Kapras V, Vyklicky V, Adamusova E, Borovska J, Vales K, Stuchlik A, Horak M,

Chodounska H and Vyklicky L, Jr. (2011) Neurosteroid modulation of N-methyl-D-

aspartate receptors: molecular mechanism and behavioral effects. Steroids 76:1409-1418.

Krintel C, Harpsoe K, Zachariassen LG, Peters D, Frydenvang K, Pickering DS, Gajhede M and

Kastrup JS (2013) Structural analysis of the positive AMPA receptor modulators CX516

and Me-CX516 in complex with the GluA2 ligand-binding domain. Acta Crystallogr D

Biol Crystallogr 69:1645-1652.

Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K,

Meltzer HY and Roth BL (2003) H1-histamine receptor affinity predicts short-term weight

gain for typical and atypical drugs. Neuropsychopharmacology 28:519-526.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Ha Ggblad J, Nilsson S and Gustafsson JK (1997)

Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of

Estrogen Receptors alpha and beta. Endocrinology 138:863-870.

Lahti RA, Evans DL, Stratman NC and Figur LM (1993) Dopamine D4 versus D2 receptor

selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J

Pharmacol 236:483-486.

Lampen A, Meyer S and Nau H (2001) Phytanic acid and docosahexaenoic acid increase the

metabolism of all-trans-retinoic acid and CYP26 gene expression in intestinal cells.

Biochim Biophys Acta 1521:97-106.

Lapinsky DJ, Aggarwal S, Huang Y, Surratt CK, Lever JR, Foster JD and Vaughan RA (2009) A

novel photoaffinity ligand for the dopamine transporter based on . Bioorg Med

Chem 17:3770-3774.

Lejeune F, Newman-Tancredi A, Audinot V and Millan MJ (1997) Interactions of (+)- and (-)-8-

and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A

49 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther receptors and their modulation of the activity of serotoninergic and neurones

in rats. J Pharmacol Exp Ther 280:1241-1249.

Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J and Janssen PA (1981) Receptor

binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 28:1015-1022.

Liegeois JF, Bruhwyler J, Damas J, Rogister F, Masereel B, Geczy J and Delarge J (1995)

Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor.

Eur J Pharmacol 273:R1-3.

Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N and

Lovenberg TW (2001) Cloning and pharmacological characterization of a fourth histamine

receptor (H(4)) expressed in bone marrow. Mol Pharmacol 59:420-426.

Loschmann PA, Chong PN, Nomoto M, Tepper PG, Horn AS, Jenner P and Marsden CD (1989)

Stereoselective reversal of MPTP-induced in the marmoset after dermal

application of N-0437. Eur J Pharmacol 166:373-380.

Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I and Taskinen J (1995) Kinetics

of human soluble and membrane-bound catechol O-methyltransferase: a revised

mechanism and description of the thermolabile variant of the . Biochemistry

34:4202-4210.

Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK,

Brossi A and Greig NH (2006) Inhibition of human acetyl- and butyrylcholinesterase by

novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J

Med Chem 49:2174-2185.

Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A and Fuks B (2004)

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug

levetiracetam. Proc Natl Acad Sci U S A 101:9861-9866.

50 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Lyon RA, Glennon RA and Titeler M (1986) 3,4-Methylenedioxymethamphetamine (MDMA):

stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology

(Berl) 88:525-526.

Maitre M, Ratomponirina C, Gobaille S, Hode Y and Hechler V (1994) Displacement of [3H]

gamma-hydroxybutyrate binding by neuroleptics and but not

by other antipsychotics. Eur J Pharmacol 256:211-214.

Malysz J, Anderson DJ, Gronlien JH, Ji J, Bunnelle WH, Hakerud M, Thorin-Hagene K, Ween H,

Helfrich R, Hu M, Gubbins E, Gopalakrishnan S, Puttfarcken PS, Briggs CA, Li J, Meyer

MD, Dyhring T, Ahring PK, Nielsen EO, Peters D, Timmermann DB and Gopalakrishnan

M (2010) In vitro pharmacological characterization of a novel selective alpha7 neuronal

nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther 334:863-874.

Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M and Briggs CA (2009) Selectivity of ABT-

089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. Biochem

Pharmacol 78:795-802.

Martin GE, Williams M, Pettibone DJ, Zrada MM, Lotti VJ, Taylor DA and Jones JH (1985)

Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors

in vitro and in vivo. J Pharmacol Exp Ther 233:395-401.

Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C and Ramirez MT (2003) Positive

allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-

1893 and MPEP. Br J Pharmacol 138:1026-1030.

Matsubayashi H, Swanson KL and Albuquerque EX (1997) Amantadine inhibits nicotinic

acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281:834-

844.

51 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Maurice T, Junien JL and Privat A (1997) Dehydroepiandrosterone sulfate attenuates dizocilpine-

induced learning impairment in mice via sigma 1-receptors. Behav Brain Res 83:159-164.

Maurice T, Urani A, Phan VL and Romieu P (2001) The interaction between neuroactive steroids

and the sigma1 receptor function: behavioral consequences and therapeutic opportunities.

Brain Res Brain Res Rev 37:116-132.

McCall RB, Lookingland KJ, Bedard PJ and Huff RM (2005) Sumanirole, a highly dopamine D2-

selective receptor agonist: in vitro and in vivo pharmacological characterization and

efficacy in animal models of Parkinson's disease. J Pharmacol Exp Ther 314:1248-1256.

Metcalf MD, Yekkirala AS, Powers MD, Kitto KF, Fairbanks CA, Wilcox GL and Portoghese PS

(2012) The delta opioid receptor agonist SNC80 selectively activates heteromeric mu-delta

opioid receptors. ACS Chem Neurosci 3:505-509.

Meyer C, Schmid R, Schmieding K, Falkenstein E and Wehling M (1998a) Characterization of

high affinity progesterone-binding membrane proteins by anti-peptide antiserum. Steroids

63:111-116.

Meyer C, Schmieding K, Falkenstein E and Wehling M (1998b) Are high-affinity progesterone

binding site(s) from porcine microsomes members of the sigma receptor family? Eur

J Pharmacol 347:293-299.

Michaelides MR, Hong Y, DiDomenico S, Jr., Asin KE, Britton DR, Lin CW, Williams M and

Shiosaki K (1995) (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-

1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist

that maintains behavioral efficacy following repeated administration and characterization

of its diacetyl (ABT-431). J Med Chem 38:3445-3447.

Mihalak KB, Carroll FI and Luetje CW (2006) Varenicline is a partial agonist at alpha4beta2 and

a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805.

52 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi

A and Peglion JL (2004a) S32504, a novel naphtoxazine agonist at dopamine D3/D2

receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with

ropinirole. J Pharmacol Exp Ther 309:903-920.

Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith

L, Jenner P, Gobert A, Peglion JL and Brocco M (2004b) S32504, a novel naphtoxazine

agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of

antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther 309:921-935.

Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet

T and Lavielle G (2000a) S33084, a novel, potent, selective, and competitive antagonist at

dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile

compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062.

Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA and Newman-Tancredi A (2002)

Differential actions of antiparkinson agents at multiple classes of receptor.

I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human

receptor subtypes. J Pharmacol Exp Ther 303:791-804.

Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Coge F, Galizzi

JP, Boutin JA, Rivet JM, Dekeyne A and Gobert A (2000b) Agonist and antagonist actions

of yohimbine as compared to at alpha(2)-adrenergic receptors (AR)s, serotonin

(5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for

the modulation of frontocortical monoaminergic transmission and depressive states.

Synapse 35:79-95.

53 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Millan MJ, Newman-Tancredi A, Quentric Y and Cussac D (2001) The "selective" dopamine D1

receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human

serotonin2C receptors. Psychopharmacology (Berl) 156:58-62.

Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S

and Piomelli D (2004) Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters

as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity

relationships, and molecular modeling studies. J Med Chem 47:4998-5008.

Motter AL and Ahern GP (2012) TRPA1 is a polyunsaturated fatty acid sensor in mammals. PLoS

One 7:e38439.

Mulder AH, Stoof JC and Horn AS (1980) Activation of presynaptic alpha-noradrenaline receptors

in rat brain by the potent dopamine-mimetic N,N-dipropyl-5,6-ADTN. Eur J Pharmacol

67:147-150.

Nash JF, Roth BL, Brodkin JD, Nichols DE and Gudelsky GA (1994) Effect of the R(-) and S(+)

isomers of MDA and MDMA on phosphatidyl turnover in cultured cells expressing

5-HT2A or 5-HT2C receptors. Neurosci Lett 177:111-115.

Neumeyer JL, Froimowitz M, Baldessarini RJ, Campbell A and Gao YG (1988)

Neuropharmacology and stereochemistry of dopamine receptor agonist and antagonist

enantiomeric pairs. J Recept Res 8:83-96.

Newman AH, Kline RH, Allen AC, Izenwasser S, George C and Katz JL (1995) Novel 4'-

substituted and 4',4"-disubstituted 3 alpha-(diphenylmethoxy) analogs as potent and

selective dopamine uptake inhibitors. J Med Chem 38:3933-3940.

Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA and Millan MJ

(2002a) Differential actions of antiparkinson agents at multiple classes of monoaminergic

54 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor

and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 303:805-814.

Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N and Millan MJ

(2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic

receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor

subtypes. J Pharmacol Exp Ther 303:815-822.

Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V and

Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A

receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256.

Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins

Slot L, Colpaert FC, Vacher B and Cussac D (2009) Signal transduction and functional

selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J

Pharmacol 156:338-353.

Nielsen EB and Andersen PH (1992) Dopamine receptor occupancy in vivo: behavioral correlates

using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists.

Eur J Pharmacol 219:35-44.

Owens MJ, Knight DL and Nemeroff CB (2001) Second-generation SSRIs: human monoamine

transporter binding profile of and R-. Biol Psychiatry 50:345-350.

Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y

and Ohta H (2000) In vitro and in vivo pharmacological characterization of J-113397, a

potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402:45-53.

Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN,

Nechushtai R, Dixon JE and Jennings PA (2007) MitoNEET is a uniquely folded 2Fe 2S

55 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S

A 104:14342-14347.

Pan W and Kastin AJ (2007) From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides.

Peptides 28:2411-2434.

Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, McAllister

G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S,

Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ and Ragan CI (1997)

Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine

D4 receptor. J Pharmacol Exp Ther 283:636-647.

Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM and Hermans E (2004) Involvement of the

sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J

Neurosci 19:2212-2220.

Perucca E (1997) A pharmacological and clinical review on topiramate, a new antiepileptic drug.

Pharmacol Res 35:241-256.

Philippens IH, Joosen MJ, Ahnaou A, Andres I and Drinkenburg WP (2014) Anti-Parkinson effects

of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model. Behav Brain

Res 269:81-86.

Pilleri M and Antonini A (2015) Therapeutic strategies to prevent and manage dyskinesias in

Parkinson's disease. Expert Opin Drug Saf 14:281-294.

Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolczewski S, Peters JU, Prinssen

E, Wichmann J, Vieira E, Muhlemann A, Gatti S, Mutel V and Malherbe P (2005)

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and

noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp

Ther 315:711-721.

56 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Portoghese PS, Sultana M and Takemori AE (1988) Naltrindole, a highly selective and potent non-

peptide delta opioid receptor antagonist. Eur J Pharmacol 146:185-186.

Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC and Deprez B (2001) From

hit to lead. Combining two complementary methods for focused library design. Application

to mu opiate ligands. J Med Chem 44:3378-3390.

Pritchett DB, Luddens H and Seeburg PH (1989) Type I and type II GABAA-

receptors produced in transfected cells. Science 245:1389-1392.

Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel

SZ, Georgic LM, Cooke LW and et al. (1995) Neurochemical and functional

characterization of the preferentially selective dopamine D3 agonist PD 128907. J

Pharmacol Exp Ther 275:1355-1366.

Purohit A, Smith C, Herrick-Davis K and Teitler M (2005) Stable expression of constitutively

activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of

antipsychotic drugs. Psychopharmacology (Berl) 179:461-469.

Quik M, Campos C, Bordia T, Strachan JP, Zhang J, McIntosh JM, Letchworth S and Jordan K

(2013) alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-

dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology 71:191-203.

Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, Gottesfeld JM and Pandolfo M (2010)

Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation

in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 5:e8825.

Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF and George SR

(2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled

to rapid activation of Gq/11 in the . Proc Natl Acad Sci U S A 104:654-659.

57 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Regunathan S and Reis DJ (1996) Imidazoline receptors and their endogenous ligands. Annu Rev

Pharmacol Toxicol 36:511-544.

Reynolds IJ and Miller RJ (1989) Ifenprodil is a novel type of N-methyl-D-aspartate receptor

antagonist: interaction with polyamines. Mol Pharmacol 36:758-765.

Richelson E and Nelson A (1984) Antagonism by of neurotransmitter receptors of

normal human brain in vitro. J Pharmacol Exp Ther 230:94-102.

Richelson E and Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus

on newer generation compounds. Life Sci 68:29-39.

Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ and Roth BL (2000)

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy

associated with and other . Circulation 102:2836-

2841.

Rover S, Cesura AM, Huguenin P, Kettler R and Szente A (1997) Synthesis and biochemical

evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of

kynurenine 3-hydroxylase. J Med Chem 40:4378-4385.

Rupprecht R, Reul JM, van Steensel B, Spengler D, Soder M, Berning B, Holsboer F and Damm

K (1993) Pharmacological and functional characterization of human mineralocorticoid and

glucocorticoid receptor ligands. Eur J Pharmacol 247:145-154.

Santangeli S, Sills GJ, Thompson GG and Brodie MJ (2002) Na(+) channel effects of remacemide

and desglycinyl-remacemide in rat cortical synaptosomes. Eur J Pharmacol 438:63-68.

Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A,

Garrido F, Mann A and et al. (1995) Nafadotride, a potent preferential dopamine D3

receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239-

1246.

58 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Scheller D, Ullmer C, Berkels R, Gwarek M and Lubbert H (2009) The in vitro receptor profile of

rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs

Arch Pharmacol 379:73-86.

Schipper J, Tulp MT and Sijbesma H (1990) Neurochemical profile of eltoprazine. Drug Metabol

Drug Interact 8:85-114.

Schlesinger F, Tammena D, Krampfl K and Bufler J (2005) Two mechanisms of action of the

derivative IEM-1460 at human AMPA-type glutamate receptors. Br J

Pharmacol 145:656-663.

Schlicker E, Werner U, Hamon M, Gozlan H, Nickel B, Szelenyi I and Gothert M (1992)

Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with

antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 105:732-738.

Schoepp DD, Ornstein PL, Salhoff CR and Leander JD (1991) Neuroprotectant effects of

LY274614, a structurally novel systemically active competitive NMDA receptor

antagonist. J Neural Transm Gen Sect 85:131-143.

Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K and

Leysen JE (1996) compared with new and reference antipsychotic drugs: in

vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73.

Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE and Prather

PL (2012) AM-251 and rimonabant act as direct antagonists at mu-opioid receptors:

implications for opioid/cannabinoid interaction studies. Neuropharmacology 63:905-915.

Seeman P, Guan HC and Hirbec H (2009) Dopamine D2High receptors stimulated by

, diethylamide, , and modafinil. Synapse 63:698-

704.

59 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN

and Price GW (1998) SB-224289--a novel selective (human) 5-HT1B receptor antagonist

with negative intrinsic activity. Br J Pharmacol 125:202-208.

Sethi KK, Vullo D, Verma SM, Tanc M, Carta F and Supuran CT (2013) Carbonic anhydrase

inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX

and XII with sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.

Bioorg Med Chem 21:5973-5982.

Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P and Honore T (1990) 2,3-Dihydroxy-6-nitro-

7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science

247:571-574.

Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley

CW, Conn PJ, Greengard P, Bezard E, Cenci MA and Surmeier DJ (2015) M4 Muscarinic

Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced

Dyskinesia. Neuron 88:762-773.

Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B,

Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M,

Witte D and Williams M (1996) ABT-431: the diacetyl prodrug of A-86929, a potent and

selective dopamine D1 receptor agonist: in vitro characterization and effects in animal

models of Parkinson's disease. J Pharmacol Exp Ther 276:150-160.

Singh S (2000) Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem

Rev 100:925-1024.

Smith U (2001) Pioglitazone: mechanism of action. Int J Clin Pract Suppl:13-18.

60 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Sousa A and Ticku MK (1997) Interactions of the neurosteroid dehydroepiandrosterone sulfate

with the GABA(A) receptor complex reveals that it may act via the site. J

Pharmacol Exp Ther 282:827-833.

Spencer DG, Jr., Glaser T and Traber J (1987) Serotonin receptor subtype mediation of the

interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine.

Psychopharmacology (Berl) 93:158-166.

Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P, Ghirardi O and Carminati P

(2006) ST 1535: a preferential A2A antagonist. Int J

Neuropsychopharmacol 9:575-584.

Subramaniam S, Donevan SD and Rogawski MA (1996) Block of the N-methyl-D-aspartate

receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther 276:161-

168.

Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van

Tol HH and Niznik HB (1991) Cloning of the gene for a human dopamine D5 receptor with

higher affinity for dopamine than D1. Nature 350:614-619.

Tatsumi M, Groshan K, Blakely RD and Richelson E (1997) Pharmacological profile of

antidepressants and related compounds at human monoamine transporters. Eur J

Pharmacol 340:249-258.

Tice MA, Hashemi T, Taylor LA, Duffy RA and McQuade RD (1994) Characterization of the

binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol Biochem

Behav 49:567-571.

Toll L, Bruchas MR, Calo G, Cox BM and Zaveri NT (2016) Nociceptin/Orphanin FQ Receptor

Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol

Rev 68:419-457.

61 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Tricklebank MD, Forler C, Middlemiss DN and Fozard JR (1985) Subtypes of the 5-HT receptor

mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur

J Pharmacol 117:15-24.

Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL and Kebabian JW (1981) Evidence that LY-

141865 specifically stimulates the D-2 dopamine receptor. Nature 292:463-465.

Uhlen S, Porter AC and Neubig RR (1994) The novel alpha-2 adrenergic radioligand [3H]-MK912

is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J

Pharmacol Exp Ther 271:1558-1565.

Van der Weide J, De Vries JB, Tepper PG and Horn AS (1986) Pharmacological profiles of three

new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur J

Pharmacol 125:273-282.

Van der Weide J, De Vries JB, Tepper PG, Krause DN, Dubocovich ML and Horn AS (1988) N-

0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur J

Pharmacol 147:249-258.

Vanover KE, Kleven MS and Woolverton WL (1991) Blockade of the discriminative stimulus

effects of cocaine in rhesus monkeys with the D(1) dopamine antagonists SCH-39166 and

A-66359. Behav Pharmacol 2:151-159.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F,

Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson

CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR and Davis RE (2006)

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-

methylpiperidin-4-yl)-N'-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-

dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor

inverse agonist. J Pharmacol Exp Ther 317:910-918.

62 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, Skoblenick K, Gupta SK, Pristupa Z,

Niznik HB, Johnson RL, Nair VD and Mishra RK (2005) Modulation of agonist binding to

human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a

peptidomimetic analog. J Pharmacol Exp Ther 315:1228-1236.

Verrico CD, Miller GM and Madras BK (2007) MDMA (Ecstasy) and human dopamine,

, and serotonin transporters: implications for MDMA-induced neurotoxicity

and treatment. Psychopharmacology (Berl) 189:489-503.

Von Voigtlander PF and Lewis RA (1982) U-50,488, a selective kappa opioid agonist: comparison

to other reputed kappa agonists. Prog Neuropsychopharmacol Biol Psychiatry 6:467-470.

Vranesic I, Ofner S, Flor PJ, Bilbe G, Bouhelal R, Enz A, Desrayaud S, McAllister K, Kuhn R and

Gasparini F (2014) AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist:

identification, SAR and pharmacological characterization. Bioorg Med Chem 22:5790-

5803.

Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL and Nelson DL (1998)

[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b

(5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol 357:17-24.

Walters MR, Dutertre M and Smith CL (2002) SKF-82958 is a subtype-selective receptor-

alpha (ERalpha ) agonist that induces functional interactions between ERalpha and AP-1.

J Biol Chem 277:1669-1679.

Wang C and Niu L (2013) Mechanism of inhibition of the GluA2 AMPA receptor channel opening

by talampanel and its : the stereochemistry of the 4-methyl group on the

diazepine ring of 2,3-benzodiazepine derivatives. ACS Chem Neurosci 4:635-644.

63 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA and Hartig PR (1992) Human serotonin

1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D

beta. Proc Natl Acad Sci U S A 89:3630-3634.

Wichmann J, Adam G, Rover S, Cesura AM, Dautzenberg FM and Jenck F (1999) 8-acenaphthen-

1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor

agonists. Bioorg Med Chem Lett 9:2343-2348.

Wong DT, Threlkeld PG, Best KL and Bymaster FP (1982) A new inhibitor of norepinephrine

uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61-65.

Wood PL, Smith T, Lane N, Khan MA, Ehrmantraut G and Goodenowe DB (2011) Oral

of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new

therapeutic strategy for Alzheimer's disease. Lipids Health Dis 10:227.

Xiang Z, Thompson AD, Brogan JT, Schulte ML, Melancon BJ, Mi D, Lewis LM, Zou B, Yang

L, Morrison R, Santomango T, Byers F, Brewer K, Aldrich JS, Yu H, Dawson ES, Li M,

McManus O, Jones CK, Daniels JS, Hopkins CR, Xie XS, Conn PJ, Weaver CD and

Lindsley CW (2011) The Discovery and Characterization of ML218: A Novel, Centrally

Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a

Rodent Model of Parkinson's Disease. ACS Chem Neurosci 2:730-742.

Yoshio R, Taniguchi T, Itoh H and Muramatsu I (2001) Affinity of serotonin receptor antagonists

and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol

86:189-195.

Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW and Quik M (2015) alpha7

nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal

damage. Mov Disord 30:1901-1911.

64 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE and Baumann

MH (2009) Evidence for the involvement of dopamine transporters in behavioral

effects of modafinil. J Pharmacol Exp Ther 329:738-746.

65 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther

66